Pharmaceutical
www.health.gov.bc.ca/pharmacare

Coverage
PharmaCare
About

• Why

• Background

become

0

0

Clopidogrel

Patients

This

attack.

Some

heart

of

clumping

48X327

blood

Patients

when

hem

This

drug

prevents

(Plavix®).

This

drugs

platelet

inhibitors.

ASA

(acetylsalicylic

acid

Aspirin®)

is

another

drug

that

prevents

platelets

from

clumping

together.

Clopidogrel

plus

ASA,

or

ASA

alone,

is

used

to

stop

blood

clots

from

forming

in

patients

who

have

unstable

angina

or

a

heart

attack.

Why was this drug reviewed?

• Before this review, clopidogrel was covered for 30 days

for patients who had unstable angina or a heart

attack. A request was made to increase this to 12 months.

Understanding the DBC Recommendation and PharmaCare Coverage Decision

Background

• When fat builds up inside blood vessels, the vessels

become narrow, and less blood and oxygen flow to the

heart. This may cause symptoms such as chest pain

(unstable angina). Chest pain can also result from a

blood clot in a blood vessel of the heart (heart attack).

• Patients who have had one event of unstable angina or

heart attack may be at risk for having a second event.

Some patients may be at a higher risk for having a second

event (high-risk patients).

• Clopidogrel has the brand name Plavix®.

◦ This drug stops blood cells called platelets from

clumping together to form a clot. It belongs to the class

drugs called platelet aggregation inhibitors.

◦ ASA (acetylsalicylic acid or Aspirin®) is another drug

that prevents platelets from clumping together.

◦ Clopidogrel plus ASA, or ASA alone, is used to stop

blood clots from forming in patients who have un-

stable angina or a heart attack.

What did the review find?

• One study shows that clopidogrel plus ASA is better than

ASA alone for preventing death, heart attack or stroke

during the first year after having unstable angina or a

heart attack.

• In the same study, patients who receive clopidogrel

plus ASA are more likely to have bleeding as a side effect

compared to the patients who receive only ASA.

• When considering both benefits and side effects of

clopidogrel plus ASA, this therapy is expected to be cost-

saving when used in high-risk patients with

unstable angina or heart attack.

What decision was made?

• Clopidogrel tablets will have limited coverage for up to

12 months, given together with ASA, for high-risk

patients with unstable angina or heart attack.

Key Term(s)

• Limited Coverage drugs are not normally considered

the first choice in treatment, or other drugs may offer better

value. To receive coverage, the patient’s physician must

submit a Special Authority request to PharmaCare. If the

request is approved, the drug is covered up to the usual

PharmaCare coverage limits. Actual reimbursement

depends on the rules of a patient's PharmaCare plan,

including any annual deductible requirement.

This document is intended for information only. It does not take the place of advice from a physician or other qualified health care provider.

Please visit us online to find out more about the Pharmaceutical Services Division and the PharmaCare program at www.health.gov.bc.ca/pharmacare. To find out more about how drugs are considered for PharmaCare coverage, visit www.health.gov.bc.ca/pharmacare/formulary.
B.C. Ministry of Health Services Drug Coverage Decisions

Clopidogrel (Plavix®) for Acute Coronary Syndrome (ACS)

Drug Class
• Platelet aggregation inhibitor

Available Dosage Forms
• 75 mg tablets

Sponsor/Requestor
• Pharmaceutical Services Division

Submission (Request) to PharmaCare
• Request to extend the Special Authority coverage for clopidogrel bisulphate (Plavix®) in combination with ASA for medically-treated patients with Acute Coronary Syndrome (ACS) from 30 days to 12 months.

Drug Benefit Council (DBC) Recommendations
• Clopidogrel limited coverage criteria be modified to:
  ○ Up to 12 months of coverage, in combination with ASA, in high-risk medically-treated acute coronary syndrome patients (diffuse three-vessel disease not amenable to revascularization, previous history of TIA, stroke or symptomatic peripheral artery disease, or patients who develop secondary ACS within the initial 30 days of clopidogrel therapy).

Reasons for the Ministry of Health Services Decision
• A literature search identified one randomized controlled trial (RCT) in medically-treated patients with ACS, hospitalized within 24 hours after onset of symptoms of ACS, without ST-segment elevation and not considered at high risk of bleeding (CURE trial). This trial compared clopidogrel plus ASA to ASA alone (n=12,562) and patients were followed for up to 12 months with the mean treatment duration of 9 months.
  ○ There was a statistically significant reduction in the first primary end point, which was a composite of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke at one month of therapy (4.3% vs. 5.4%, absolute risk reduction [ARR] of 1.1% and a number needed to treat [NNT] of 91) and at the end of the study period (9.3% vs. 11.4%, ARR = 2.1%, and NNT = 48).
  ○ There was a statistically significant reduction in the second primary end point, which was a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or refractory ischemia at one month of therapy (ARR = 1.5%) and at the end of the study period (ARR = 2.3%).
  ○ There was a statistically significant reduction in myocardial infarction (ARR = 1.5%) and severe ischemia (ARR = 1.0%) at the end of the study period.
  ○ Compared to the ASA group, the clopidogrel plus ASA group had a statistically significant increase in major bleeding (absolute risk increase [ARI] = 0.5%, and number needed to harm [NNH] = 200) at one month and at the end of the study period (ARI = 1.0%, NNH = 100), minor bleeding at the end of the study period (ARI = 2.7%, NNH = 37), and total bleeding complications at the end of the study period (ARI = 3.5%, NNH = 29).

• Due to both the incremental clinical benefits and bleeding risks associated with clopidogrel plus ASA, there is still uncertainty as to the overall net clinical benefits and cost-effectiveness in this patient population. As a result, the DBC is more comfortable recommending coverage in a defined high-risk sub-population rather than all medically-treated ACS patients.
  ○ While there is limited pharmacoeconomic evidence to guide the recommendation, treatment with clopidogrel plus ASA for up to 12 months is expected to be more cost-effective when used in the high-risk sub-population than if used in all medically-treated ACS patients.

Continued on page 3
Reasons for the Ministry of Health Services Decision (continued)

- The limited coverage criteria definition of high-risk patients was based on the recommendation of the DBC and consultations with external clinicians.

Decision and Status

Limited coverage criteria:
- For high-risk, medically-treated patients following hospital-diagnosed Acute Coronary Syndrome in combination with ASA. High-risk patients are those who have:
  - a history of arterial disease; OR
  - a recurrent vascular event while on ASA alone or within the initial 30 days of combination clopidogrel plus ASA; OR
  - a contraindication to or a pattern of coronary artery disease not amenable to mechanical revascularization.

- Notes:
  1. Acute Coronary Syndrome (ACS) is defined as unstable angina or non-ST elevation myocardial infarction.
  2. A history of arterial disease is defined as previous transient ischemic attack (TIA), stroke, or symptomatic peripheral artery disease.
  3. Clinical judgement is warranted to assess the increased bleeding risk of combining clopidogrel with ASA and/or oral anticoagulants.

Approval Period/Duration:
- Up to twelve months
- No coverage for ASA
- Effective March 16, 2010

Key Term(s)

- **Limited Coverage** drugs are not normally considered the first choice in treatment, or other drugs may offer better value. To receive coverage, the patient's physician must submit a Special Authority request to PharmaCare. If the request is approved, the drug is covered up to the usual PharmaCare coverage limits. Actual reimbursement depends on the rules of a patient's PharmaCare plan, including any annual deductible requirement.